Richard S Levy

CIK 1454983 · EVP, Chief Drug Dev Officer · last filed 2026-06-02

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$15.96M

Companies

6

Total Filings

97

Lifetime Open-Market Net

-$69.59M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KNSA Director 21,956 $51.89 $1.14M $0 14 2026-06-02
MDGL Director 26,576 $480.77 $12.78M -$19.89M 22 2026-05-22
KOD Director 250 $34.06 $8.5K $44.3K 9 2025-07-02
TARA Director 51,000 $3.90 $198.9K $127.6K 9 2025-06-13
CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted Director $33.99 $0 2 2021-06-04
INCY EVP, Chief Drug Dev Officer 16,926 $108.53 $1.84M -$49.87M 40 2016-01-08

Recent Filings · Page 5 of 10

97 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2020-07-02 KNSA Grant (A) $0 EDGAR
2020-07-02 KOD Grant (A) $0 EDGAR
2020-06-18 MDGL Grant (A) $0 EDGAR
2020-06-11 TARA Grant (A) $0 EDGAR
2020-06-10 KOD Grant (A) $0 EDGAR
2020-04-06 CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted Grant (A) $0 EDGAR
2020-03-24 KOD Buy (P) +1,000 $44.3K EDGAR
2020-01-13 TARA Grant (A) +31,000 $0 EDGAR
2019-07-01 MDGL Grant (A) $0 EDGAR
2019-06-05 KOD Grant (A) $0 EDGAR
Showing 4150 of 97
Page 5 of 10
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.